Richard Gilbertson
#88,508
Most Influential Person Now
British paediatric oncology clinician scientist
Richard Gilbertson's AcademicInfluence.com Rankings
Richard Gilbertsonmedical Degrees
Medical
#1669
World Rank
#2033
Historical Rank
Oncology
#193
World Rank
#199
Historical Rank
Richard Gilbertsonphilosophy Degrees
Philosophy
#10210
World Rank
#13973
Historical Rank
Logic
#7119
World Rank
#8767
Historical Rank
Download Badge
Medical Philosophy
Why Is Richard Gilbertson Influential?
(Suggest an Edit or Addition)According to Wikipedia, Professor Richard James Gilbertson is a paediatric oncology clinician scientist and a Senior Group Leader at the Cancer Research UK Cambridge Institute, University of Cambridge. He is the Li Ka Shing Chair of Oncology, and Director of the CRUK Cambridge Major Centre and the Children's Brain Tumour Centre of Excellence.
Richard Gilbertson's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- A perivascular niche for brain tumor stem cells. (2007) (2114)
- Molecular subgroups of medulloblastoma: the current consensus (2011) (1507)
- Somatic Histone H3 Alterations in Paediatric Diffuse Intrinsic Pontine Gliomas and Non-Brainstem Glioblastomas (2012) (1327)
- Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas (2012) (855)
- Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. (2015) (782)
- Radial glia cells are candidate stem cells of ependymoma. (2005) (773)
- Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. (2006) (761)
- Novel mutations target distinct subgroups of medulloblastoma (2012) (746)
- Making a tumour's bed: glioblastoma stem cells and the vascular niche (2007) (703)
- Prominin1 marks intestinal stem cells that are susceptible to neoplastic transformation (2008) (665)
- Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. (2006) (660)
- Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas (2013) (655)
- Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. (2011) (643)
- Subtypes of medulloblastoma have distinct developmental origins (2010) (581)
- Medulloblastomics: the end of the beginning (2012) (559)
- The brain tumor microenvironment (2011) (508)
- Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma (2014) (496)
- Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups (2011) (461)
- C11orf95-RELA fusions drive oncogenic NF-κB signaling in ependymoma (2014) (450)
- Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma (2009) (430)
- Challenges to curing primary brain tumours (2019) (414)
- Dual and opposing roles of primary cilia in medulloblastoma development (2009) (376)
- The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes (2014) (345)
- Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. (2003) (339)
- The brain tumor microenvironment (2011) (333)
- Cross-species genomics matches driver mutations and cell compartments to model ependymoma (2010) (326)
- Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. (2015) (325)
- Medulloblastoma: signalling a change in treatment. (2004) (311)
- The origins of medulloblastoma subtypes. (2008) (290)
- The miR-17∼92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma (2009) (289)
- Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. (2005) (287)
- A mouse model of the most aggressive subgroup of human medulloblastoma. (2012) (273)
- Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. (2004) (268)
- Wnt/Wingless Pathway Activation and Chromosome 6 Loss Characterise a Distinct Molecular Sub-Group of Medulloblastomas Associated with a Favourable Prognosis (2006) (260)
- Critical Role for the DNA Sensor AIM2 in Stem Cell Proliferation and Cancer (2015) (240)
- The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants (2016) (220)
- Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort (2018) (212)
- A molecular fingerprint for medulloblastoma. (2003) (212)
- Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study (2013) (209)
- Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype. (2016) (206)
- Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice (2004) (202)
- Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. (2007) (194)
- DDX3X acts as a live-or-die checkpoint in stressed cells by regulating NLRP3 inflammasome (2019) (186)
- Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. (2010) (183)
- Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. (2010) (177)
- ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. (2002) (176)
- Regression of experimental medulloblastoma following transfer of HER2-specific T cells. (2007) (167)
- ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. (2003) (165)
- The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. (2005) (164)
- Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells (2008) (160)
- The Choroid Plexus and Cerebrospinal Fluid: Emerging Roles in Development, Disease, and Therapy (2013) (151)
- Phase I study of everolimus in pediatric patients with refractory solid tumors. (2007) (150)
- Genetic abnormalities detected in ependymomas by comparative genomic hybridisation (2002) (149)
- Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. (2011) (149)
- A prognostic gene expression signature in infratentorial ependymoma (2012) (133)
- ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. (2003) (130)
- WNT signaling increases proliferation and impairs differentiation of stem cells in the developing cerebellum (2012) (128)
- Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. (2008) (126)
- Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study. (2014) (121)
- Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. (2018) (120)
- Molecular Characterization of the Pediatric Preclinical Testing Panel (2008) (116)
- Multi-organ Mapping of Cancer Risk (2016) (114)
- What's new in neuro-oncology? Recent advances in medulloblastoma. (2003) (112)
- cIMPACT‐NOW update 7: advancing the molecular classification of ependymal tumors (2020) (112)
- Molecular Insights into Pediatric Brain Tumors Have the Potential to Transform Therapy (2014) (111)
- Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. (2010) (111)
- PDGFRB is overexpressed in metastatic medulloblastoma (2003) (108)
- The G-protein Alpha Subunit Gsα Is A Tumor Suppressor In Sonic Hedgehog-driven Medulloblastoma (2014) (106)
- Cancer-associated DDX3X mutations drive stress granule assembly and impair global translation (2016) (106)
- Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling. (2003) (103)
- An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. (2011) (101)
- Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma. (2008) (100)
- Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. (2011) (93)
- A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat (2011) (78)
- Genetic alterations in mouse medulloblastomas and generation of tumors de novo from primary cerebellar granule neuron precursors. (2007) (77)
- A Phase I Study of 17-Allylaminogeldanamycin in Relapsed/Refractory Pediatric Patients with Solid Tumors: A Children's Oncology Group Study (2007) (77)
- Rapid Diagnosis of Medulloblastoma Molecular Subgroups (2011) (77)
- Stem cells of ependymoma (2006) (74)
- A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. (2009) (74)
- Impact of radiotherapy parameters on outcome in the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 study of preradiotherapy chemotherapy for M0-M1 medulloblastoma. (2002) (73)
- Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. (2010) (72)
- The TP53-ARF tumor suppressor pathway is frequently disrupted in large/cell anaplastic medulloblastoma. (2004) (70)
- Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma (2021) (68)
- Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups (2014) (68)
- Defining a role for Sonic hedgehog pathway activation in desmoplastic medulloblastoma by identifying GLI1 target genes (2007) (68)
- Cancer: Resolving the stem-cell debate (2012) (67)
- Novel ERBB4 juxtamembrane splice variants are frequently expressed in childhood medulloblastoma (2001) (67)
- Tumorigenesis in the brain: location, location, location. (2007) (67)
- A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A children's oncology group phase 1 consortium study (2013) (67)
- Global analysis of the medulloblastoma epigenome identifies disease-subgroup-specific inactivation of COL1A2. (2008) (64)
- Cross-Species Genomics Identifies TAF12, NFYC, and RAD54L as Choroid Plexus Carcinoma Oncogenes. (2015) (59)
- A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. (2010) (57)
- A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study (2013) (55)
- Epigenetic inactivation of MCJ (DNAJD1) in malignant paediatric brain tumours (2006) (54)
- Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study. (2012) (53)
- An in vivo screen identifies ependymoma oncogenes and tumor-suppressor genes (2015) (52)
- Paediatric embryonic brain tumours. biological and clinical relevance of molecular genetic abnormalities. (2002) (50)
- Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). (2021) (50)
- An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN) (2015) (49)
- Histological Predictors of Outcome in Ependymoma are Dependent on Anatomic Site Within the Central Nervous System (2013) (48)
- mTORC1-Mediated Inhibition of 4EBP1 Is Essential for Hedgehog Signaling-Driven Translation and Medulloblastoma. (2017) (45)
- A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-κB (2018) (44)
- UPLC-MS-ELSD-PDA as a powerful dereplication tool to facilitate compound identification from small-molecule natural product libraries. (2014) (44)
- Orthotopic models of pediatric brain tumors in zebrafish (2014) (44)
- Mutational analysis of PDGFR-RAS/MAPK pathway activation in childhood medulloblastoma. (2006) (41)
- Identification of interleukin-13 receptor alpha2 chain overexpression in situ in high-grade diffusely infiltrative pediatric brainstem glioma. (2008) (41)
- Mapping Cancer Origins (2011) (40)
- Pten deletion causes mTorc1-dependent ectopic neuroblast differentiation without causing uniform migration defects (2012) (39)
- Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study (2015) (36)
- TP53 mutations in favorable-risk Wnt/Wingless-subtype medulloblastomas. (2011) (35)
- Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells (2017) (35)
- MEDB-74. Serial assessment of measurable residual disease in medulloblastoma liquid biopsies (2021) (35)
- Medulloblastoma Sensitivity to 17-Allylamino-17-demethoxygeldanamycin Requires MEK/ERK* (2003) (35)
- Continuous Delivery of IFN-β Promotes Sustained Maturation of Intratumoral Vasculature (2007) (34)
- Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis (2020) (34)
- DDX3X Suppresses the Susceptibility of Hindbrain Lineages to Medulloblastoma. (2020) (34)
- Assessing telomeric DNA content in pediatric cancers using whole-genome sequencing data (2012) (33)
- Bevacizumab (BVZ)‐associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT‐11) (2013) (33)
- ZFTA-RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma. (2021) (30)
- A novel Atg5-shRNA mouse model enables temporal control of Autophagy in vivo (2018) (30)
- Molecular Biology of Medulloblastoma: Will It Ever Make a Difference to Clinical Management? (2005) (30)
- ERBB2 in pediatric cancer: innocent until proven guilty. (2005) (24)
- Brain Tumors Provide New Clues to the Source of Cancer Stem Cells: Does Oncology Recapitulate Ontogeny? (2006) (24)
- Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma. (2015) (24)
- ZFTA-translocations constitute ependymoma chromatin remodeling and transcription factors. (2021) (22)
- Cross-species genomics reveals oncogenic dependencies in ZFTA/C11orf95 fusion-positive supratentorial ependymomas. (2021) (22)
- Cancer Treatment in the Genomic Era. (2019) (20)
- A phase I pharmacokinetic trial of sonic hedgehog (SHH) antagonist GDC-0449 in pediatric patients with recurrent or refractory medulloblastoma: A Pediatric Brain Tumor Consortium study (PBTC 25). (2010) (19)
- Rethinking brain tumors: the fourth Mouse Models of Human Cancers Consortium nervous system tumors workshop. (2008) (19)
- Corrigendum: C11orf95–RELA fusions drive oncogenic NF-κB signalling in ependymoma (2014) (19)
- Molecular profiling of pediatric brain tumors: Insight into biology and treatment (2009) (18)
- Brain Tumors: Challenges and Opportunities to Cure. (2017) (17)
- A procedure to statistically evaluate agreement of differential expression for cross-species genomics (2011) (15)
- Defining future directions in spinal cord tumor research: proceedings from the National Institutes of Health workshop. (2010) (15)
- DNA methylation signature is prognostic of choroid plexus tumor aggressiveness (2019) (14)
- A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study. (2015) (14)
- Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas (2021) (13)
- Mechanically matching the rheological properties of brain tissue for drug-delivery in human glioblastoma models. (2021) (13)
- LOSS OF 10Q IS AN INDICATOR OF POOR OUTCOME IN SHH SUBGROUP MEDULLOBLASTOMA (2012) (13)
- Maturation Block in Childhood Cancer. (2021) (13)
- Myc and Loss of p53 Cooperate to Drive Formation of Choroid Plexus Carcinoma. (2019) (13)
- Preclinical studies of 5-fluoro-2′-deoxycytidine and tetrahydrouridine in pediatric brain tumors (2015) (13)
- Erratum: C11orf95-RELA fusions drive oncogenic NF-ΰ B signalling in ependymoma (Nature (2014) 506 (451-455 ) DOI:10.1038/nature13109) (2014) (12)
- A prospective phase II study to determine the efficacy of GDC 0449 (vismodegib) in adults with recurrent medulloblastoma (MB): A Pediatric Brain Tumor Consortium study (PBTC 25B). (2013) (11)
- Driving Glioblastoma to Drink (2014) (10)
- The niche revealed. (2008) (10)
- To infinium, and beyond! (2010) (10)
- Preclinical Modeling of Image-Guided Craniospinal Irradiation for Very-High-Risk Medulloblastoma. (2019) (9)
- Exome sequencing analysis of murine medulloblastoma models identifies WDR11 as a potential tumor suppressor in Group 3 tumors. (2017) (9)
- Establishing a Preclinical Multidisciplinary Board for Brain Tumors (2018) (9)
- High-grade glioma: can we teach an old dogma new tricks? (2006) (8)
- Pediatric Hematology and Oncology: Scientific Principles and Clinical Practice (2010) (7)
- A Novel Atg 5-shRNA Mouse Model Enables Temporal Control of 1 Autophagy in vivo 2 3 (2017) (7)
- Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study (2015) (7)
- A phase I trial and pharmacokinetic (PK) study of vorinostat (SAHA) in combination with 13 cis-retinoic acid (13cRA) in children with refractory neuroblastomas, medulloblastomas, primitive neuroectodermal tumors (PNETs), and atypical teratoid rhabdoid tumor (2008) (7)
- Brain Cancer Stem Cells as Targets of Novel Therapies (2009) (7)
- A phase I trial of vorinostat in children with refractory solid tumors: A Children's Oncology Group Study (2007) (6)
- The NALCN channel regulates metastasis and nonmalignant cell dissemination (2022) (6)
- ERBB 1 Is Amplified and Overexpressed in High-grade Diffusely Infiltrative Pediatric Brain Stem Glioma 1 (2003) (6)
- Prometastatic Genes in Medulloblastoma and Several other S 100 A 4 ERBB 2 UpRegulates Updated (2002) (6)
- BI-30CHARACTERIZATION OF L1CAM AS A CLINICAL MARKER FOR THE C11orf95-RELA FUSION IN SUPRATENTORIAL EPENDYMOMAS (2014) (5)
- Finding the perfect partner for medulloblastoma prognostication. (2011) (5)
- There's a time and a place for MYCN. (2012) (5)
- Harnessing brain development to understand brain tumours (2021) (4)
- DDX3X acts as a live-or-die checkpoint in stressed cells by regulating NLRP3 inflammasome (2019) (4)
- Highlights of Children with Cancer UK’s Workshop on Drug Delivery in Paediatric Brain Tumours (2016) (4)
- A pediatric phase I trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A Children's Oncology Group Phase I Consortium Study. (2011) (4)
- Primary cilia control translation and the cell cycle in medulloblastoma (2022) (4)
- The miR-17 similar to 92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma (2009) (4)
- Exome sequencing analysis of murine medulloblastoma models identifies WDR11 as a potential tumor suppressor in Group 3 tumors (2017) (3)
- A pediatric phase I trial and pharmacokinetic (PK) study of erlotinib (ERL) followed by the combination of ERL with temozolomide (TMZ): A Children's Oncology Group Study. (2006) (3)
- Pten deletion causes mTorc1-dependent ectopic neuroblast differentiation without causing uniform migration defects (2012) (3)
- Simvastatin Hydroxy Acid Fails to Attain Sufficient Central Nervous System Tumor Exposure to Achieve a Cytotoxic Effect: Results of a Preclinical Cerebral Microdialysis Study (2016) (3)
- MB-19MEDULLOBLASTOMA SUBTYPES SPECIFY INTER-TUMORAL VASCULAR BLOOD BRAIN BARRIER HETEROGENEITY (2015) (3)
- Nature GeNetics ADVANCE ONLINE PUBLICATION (2013) (3)
- KCNQ gene family members act as both tumor suppressors and oncogenes in gastrointestinal cancers (2020) (3)
- Human fetal cerebellar cell atlas informs medulloblastoma origin and oncogenesis (2022) (2)
- Molecular subtypes in medulloblastoma: an International meta-analysis for profiles, genetic aberrations, clinicopathological features AND SURVIVAL (2011) (2)
- Nuclear reprogramming and the cancer genome (2013) (2)
- A phase I trial of MK-0752 in children with recurrent or refractory CNS malignancies: A Pediatric Brain Tumor Consortium study. (2010) (2)
- Pediatric hematology and oncology (2013) (1)
- The cancer stem cell niche in medulloblastoma. (2006) (1)
- Abstract 3448: Subtypes of medulloblastoma have distinct developmental origins (2011) (1)
- THE ROLE OF POTASSIUM CHANNELS IN THE PATHOGENESIS OF GASTROINTESTINAL CANCERS AND THERAPEUTIC POTENTIAL (2022) (1)
- Comprar Pediatric Hematology And Oncology. Scientific Principles And Clinical Practice | Edward Estlin | 9781405153508 | Wiley (2010) (1)
- EPEN-25. A novel spontaneous model of ZFTA-RELA fusion ependymoma (2022) (1)
- Correction to: DNA methylation signature is prognostic of choroid plexus tumor aggressiveness (2019) (1)
- Abstract 2492: Integrated genomics on molecular subgroups in medulloblastoma (2012) (1)
- Assessing telomeric DNA content in pediatric cancers using whole-genome sequencing data (2012) (1)
- Erratum: Radial glia cells are candidate stem cells of ependymoma (Cancer Cell (October 2005) 8 (323-335)) (2006) (1)
- 腫瘍組織学は、平均リスクと高リスク髄芽細胞腫において無再発生存率の重要な独立予後因子である:前向き共同試験(SJMB96)の結果 (2007) (1)
- Epigenetic sub-classification and risk-stratification of medulloblastoma using DNA methylomics (2012) (1)
- Developing treatment strategies for rare cancers (2011) (1)
- Abstract 3442: TP53 mutations in favorable risk WNT subtype medulloblastomas (2011) (0)
- Reply to ‘Assembling the brain trust: the multidisciplinary imperative in neuro-oncology’ (2019) (0)
- MB-32MEDULLOBLASTOMA GENOTYPE DICTATES BLOOD BRAIN BARRIER PHENOTYPE (2016) (0)
- Analysis of ependymomas using comparative genomic hybridisation (2001) (0)
- Abstract A52: An interspecies genomics based high‐throughput screen for novel treatments of ependymoma (2009) (0)
- Abstract 4645: Clofarabine, a potent anticancer compound with limited penetration in an orthotopic murine model of ependymoma (2014) (0)
- PCM-01DIFFERENTIAL RESPONSES OF MURINE MODELS OF SUPRATENTORIAL EPENDYMOMA TO GEMCITABINE AS MEASURED BY MRI AND PET-CT (2016) (0)
- Reflections on a Successful 2010 (2011) (0)
- Khalida WaniTerri S. ArmstrongElizabeth Vera-BolanosAditya RaghunathanDavid Ellison • Richard GilbertsonBrian VaillantStewart GoldmanRoger J. PackerMaryam FouladiIan Pollack • Tom MikkelsenMichael PradosAntonio OmuroRiccardo SoffiettiAlicia LedouxCharmaine Wilson • Lihong LongMark R. GilbertKen Alda (2012) (0)
- PDTM-45. MECHANISM OF NEURAL STEM CELL TRANSFORMATION BY C11ORF95-RELA TRANSLOCATIONS (2019) (0)
- Challenges and opportunities for physician-scientists in advancing cancer research. (2022) (0)
- Expression of the ErbB-Neuregulin Signaling Network during Human Cerebellar Development : Implications for the Biology of Mceluilohiastonia 1 (2006) (0)
- Abstract 2479: TP53 status as a marker of recurrence and survival in choroid plexus carcinomas (2012) (0)
- PATH-04. Array-based global DNA Methylation profiling of mouse brain tumors allows comparison to human tumors (2022) (0)
- 896 Anatomic Variants of Ependymoma Arise from Distinct Subsets of Radial Glial Cells. (2005) (0)
- MODL-08. OPTIMIZATION OF A NOVEL LOCAL DELIVERY SYSTEM FOR THE TREATMENTS OF SUPRATENTORIAL EPENDYMOMA (2020) (0)
- Abstract PR016: Aging modulates the tumor microenvironment of pancreatic cancer (2022) (0)
- Abstract 2789: Investigating the role of DNA methylation in pediatric choroid plexus tumors (2016) (0)
- LGG Nat Genet Supplemental data 2013 (2013) (0)
- Abstract A006: The NALCN channel regulates metastasis and non-malignant cell dissemination (2023) (0)
- Preclinical Modeling of Clinically Relevant Radiation Therapy for Treatment of High-Risk Medulloblastoma (2017) (0)
- EPEN-03. ZFTA/C11ORF95 FUSIONS DRIVE SUPRATENTORIAL EPENDYMOMA VIA SHARED ONCOGENIC MECHANISMS (2021) (0)
- Advances and Challenges in Pediatric and Childhood Cancers. (2020) (0)
- Correction to: DNA methylation signature is prognostic of choroid plexus tumor aggressiveness (2019) (0)
- DNA methylation signature is prognostic of choroid plexus tumor aggressiveness (2019) (0)
- PNR-08NEWLY DISCOVERED ONCOGENES DRIVING AND MAINTAINING CHOROID PLEXUS CARCINOMA PROVIDE POTENTIALLY DRUGGABLE TARGETS (2016) (0)
- Faculty Opinions recommendation of Notch and EGFR pathway interaction regulates neural stem cell number and self-renewal. (2010) (0)
- The Kruppel-like factor 4 (KLF4) tumor suppressor gene is silenced by genetic and epigenetic mechanisms in medulloblastoma (2007) (0)
- Abstract 3002: Identification of frequently altered protein networks in ependymomas (2012) (0)
- PCM-22A NEW APPROACH OF PRECLINICAL TESTING OF CHEMOTHERAPIES - AN EXAMPLE OF BRAIN TUMOUR THERAPY (2016) (0)
- Abstract 661: Identification of epigenomic markers on chromosome 11 that distinguish between choroid plexus carcinoma (CPC) and papilloma (CPP). (2013) (0)
- Phase I study of vandetanib (ZD6474) administered during and after irradiation (RT) in children with diffuse intrinsic pontine glioma (DIPG). (2016) (0)
- A comprehensive view of the structure and expression of the ependymoma genome at presentation and relapse (2009) (0)
- A Preclinical Multidisciplinary Brain Tumor Board (2017) (0)
- Genetic abnormalities detected in genomic hybridisation epenclymomas by comparative (2002) (0)
- Abstract 1434: A mouse model of the most aggressive subgroup of human medulloblastoma (2012) (0)
- Abstract SY10-03: Cell of origin in pediatric medulloblastomas (2012) (0)
- CLIN-PEDIATRICS CLINICAL RESEARCH (2012) (0)
- Abstract PL02-03: Genomic mapping of cancer origins (2012) (0)
- Abstract 3449: Epigenomics identifies conserved DNA methylation events associated with medulloblastoma development in humans and mice (2011) (0)
- MPTH-26MOLECULAR REFINEMENT OF PEDIATRIC POSTERIOR FOSSA EPENDYMOMA (2015) (0)
- Abstract IA23: Medulloblastoma subgroup-specific mutations model the tumor microenvironment (2015) (0)
- Abstract LB-63: Cell ground state dictates cancer susceptibility across organs (2014) (0)
- Exploiting biology for therapeutic gain (2004) (0)
- Abstract 3444: Enforced expression of MycN and C-Myc induces different medulloblastoma subtypes (2011) (0)
- MBCL-44. THE MOLECULAR AND CLINICAL LANDSCAPE OF INFANT MEDULLOBLASTOMA (iMB): RESULTS AND MOLECULAR ANALYSIS FROM A PROSPECTIVE, MULTICENTER PHASE II TRIAL (SJYC07) (2018) (0)
- EP-03MOLECULAR CLASSIFICATION OF EPENDYMAL TUMORS ACROSS ALL CNS COMPARTMENTS, HISTOPATHOLOGICAL GRADES AND AGE GROUPS (2015) (0)
- PCM-06ACCURATE PRECLINICAL TRIALS OF NEW EPENDYMOMA THERAPIES. (2016) (0)
- Abstract 3111: Identification of genes that frequently exhibit copy number alterations in pediatric ependymomas (2014) (0)
- MEDB-32. Reducing treatment-related toxicity for children with WNT-activated medulloblastoma (2022) (0)
- Abstract 4759: Integrated in vitro and in vivo screening of tumor and normal neural stem cells identifies potential new treatments of ependymoma (2011) (0)
- Abstract 3280: Sequencing approaches define the mutation and fusion landscape of choroid plexus carcinomas (2015) (0)
- Luciferase-based detection of minimal size metastases (2005) (0)
- Future Treatments of Ependymoma (2010) (0)
- MycandLossofp53Cooperate toDriveFormation of Choroid Plexus Carcinoma (2019) (0)
- A Year of Continued Growth and Success (2012) (0)
- Abstract IA18: Mapping cancer origins (2014) (0)
- Stem cells, mice, and men: Integrating human and mouse genomics to advance understanding of the biology and treatment of brain tumors (2006) (0)
- Abstract #5685: DNA methylation profiling of medulloblastoma reveals distinct epigenetic disease subgroups associated with developmental signaling pathway activation and clinical disease features (2009) (0)
- Identification of genes involved in medulloblastoma formation (2006) (0)
- MBRS-20. CSF-DERIVED CIRCULATING TUMOR DNA AS A BIOMARKER FOR DISEASE PROGRESSION AND TUMOR EVOLUTION IN MEDULLOBLASTOMA (2020) (0)
- Abstract #1940: Prominin1/CD133 marks adult intestinal stem cells that are susceptible to neoplastic transformation (2009) (0)
- PM-15C11orf95-RELA FUSION ALONE IS SUFFICIENT TO FORM HUMAN SUPRATENTORIAL EPENDYMOMA-LIKE TUMOR IN MICE (2014) (0)
- Abstract PR11: Medulloblastoma-associated mutations in the DEAD box RNA helicase DDX3X impair protein translation (2013) (0)
- DNA methylomics identifies clinically significant epigenetic subgroups of medulloblastoma (2010) (0)
- 193 The identification of new therapies for ependymoma subgroups (2014) (0)
- Study of 17-Allylaminogeldanamycin in Relapsed / Refractory Pediatric Patients with SolidTumors : AChildren ’ s Oncology Group Study (2007) (0)
- O8.10A MODEL FOR RESEARCH INITIATIVES FOR RARE CANCERS: THE COLLABORATIVE EPENDYMOMA RESEARCH NETWORK (CERN). (2014) (0)
- EPEN-14. GENERATION OF A C11orf95-RELA FUSION TARGETING ANTIBODY AS A DIAGNOSTIC TOOL FOR SUPRATENTORIAL EPENDYMOMA (2020) (0)
- Abstract IA21: Pediatric medulloblastoma: Drug screens and preclinical studies (2015) (0)
- Use of whole genome sequencing to identify novel mutations in distinct subgroups of medulloblastoma. (2012) (0)
- Abstract 4873: Comprehensive analysis of 160 whole-genome sequences reveals striking telomere alteration patterns in 9 pediatric cancers (2012) (0)
- MEDU-32. ADVANCING PRECLINICAL MODELING OF HIGH RISK MEDULLOBLASTOMA BY PERFORMING CLINICALLY-RELEVANT RADIOTHERAPY ON PATIENT-DERIVED XENOGRAFTS (2017) (0)
This paper list is powered by the following services:
Other Resources About Richard Gilbertson
What Schools Are Affiliated With Richard Gilbertson?
Richard Gilbertson is affiliated with the following schools:
